Context Therapeutics, Inc. (CNTX)

Over the past six months, Context Therapeutics' stock has experienced fluctuations, reaching a 52-week high of $2.85 on January 30, 2026. The company reported a net loss of $9.7 million in Q3 2025, an improvement from $17.5 million in Q3 2024, with an EPS of -$0.10 missing consensus estimates. Jones Trading initiated coverage with a "Buy" recommendation in December 2025, and the company announced inducement grants in January 2026.

Context Therapeutics does not experience traditional demand seasonality as a clinical-stage biopharmaceutical company. The demand for its offerings is driven by clinical trial progress, regulatory approvals, and market adoption.

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell engaging bispecific antibodies for solid tumors, particularly female hormone-dependent cancers like breast, ovarian, and endometrial cancers. Their pipeline includes CTIM-76, CT-95, and CT-202, each targeting different cancer-related proteins to redirect T-cell-mediated lysis toward malignant cells. The company was founded in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and primarily conducts clinical research in North America, with plans for potential global expansion.

Context Therapeutics has generally maintained a positive brand reputation among analysts, with a consensus rating of "Moderate Buy" or "Strong Buy". Analysts have highlighted the promising early clinical activity and favorable safety profile of CTIM-76, along with the company's robust cash position projected to last through 2027. Concerns include a decline in research and development expenses in Q3 2024, net losses, potential safety issues, competitive pressures, and regulatory uncertainties.

Context Therapeutics has significant institutional ownership, with approximately 85.26% of its stock held by institutions and 6.45% by individuals. Major institutional owners include MPM Oncology Impact Management LP, Avidity Partners Management LP, Nextech Invest, Ltd., Deep Track Capital, LP, and Blue Owl Capital Holdings LP.